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Abstract  
Introduction: Several rheumatoid arthritis (RA) susceptibility loci have also been 
found to be associated with psoriatic arthritis (PsA), demonstrating that there is a 
degree of genetic overlap between various autoimmune diseases. We sought to 
investigate whether single nucleotide polymorphisms (SNPs) mapping to previously 
reported RA and/or PsA susceptibility loci, including PLCL2, CCL21, REL, STAT4, 
CD226, PTPN22 and TYK2, are associated with risk for the two diseases in a 
genetically homogeneous Greek population. 
Methods: A total of 392 RA patients, 126 PsA patients and 521 healthy age and sex 
matched controls from Greece were included. Genotyping of the SNPs was performed 
with Taqman primer-probe sets. Bioinformatic analysis was performed using BlastP, 
Pymol and Maestro and Desmond (Schrodinger Inc.).  
Results: A significant association was detected between the GC genotype of 
rs34536443 (TYK2) in both the PsA and RA cohorts. The C allele of this SNP was 
associated with PsA only. Evidence for association with PsA was also found for the 
GG genotype and G allele of the rs10181656 SNP of STAT4. The TC genotype of the 
rs763361 SNP of CD226 was associated with PsA only. 
Conclusions: Genetic overlap between PsA and RA was detected for the rs34536443 
SNP of TYK2 gene within a Greek population. An association of STAT4 (rs10181656) 
with PsA was confirmed whilst CD226 (rs763361) was associated with PsA but not 
RA, in contrast to previous reports.  The different findings of this study compared to 
previous ones highlights the importance of comparative studies that include various 
ethnic or racial populations.   
Keywords: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), genetic association, 
gene polymorphisms  
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Introduction 
Autoimmune diseases affect approximately 5% of the human population; however the 
genes and mechanisms involved still remain obscure. There is accumulating evidence 
that common genetic factors might predispose to multiple autoimmune disorders, thus 
indicating the pleiotropic effect of these gene polymorphisms. Such variants are by 
definition known as primary causal risk factors. In this framework, it has been 
documented that common variants of PTPN22 (1-7), CTLA-4 (8-12), STAT4 (13-16), 
TRAF1/C5 (17, 18) and CD40 (19-22) are associated with different autoimmune 
disorders. 
In recent years, a large number of novel genes associated with rheumatoid arthritis 
(RA) have been identified (23), especially with the use of the Immunochip, which has 
brought the number of RA-susceptibility loci in Caucasians to 48 (45 non HLA loci 
plus three HLA loci) (24) and in all populations to 101 (25). RA is a systemic 
multifactorial disease that results from a complex interplay between genetic and 
environmental factors (26). The serum of most RA patients contains various auto-
antibodies, such as rheumatoid factor (RF) or anti-citrullinated protein antibodies 
(ACPAs), the presence of which constitutes one of the new classification criteria for 
RA (27).  
The clinical features of RA resemble those of other autoimmune diseases, especially 
that of psoriatic arthritis (PsA), an inflammatory arthritis that is associated with 
Psoriasis (PS). For example, both diseases are characterized by the occurrence of an 
inflammatory arthritis in peripheral synovial joints. Patients also respond to similar 
therapies including methotrexate and anti-tumour necrosis factor biologic treatment 
(28). This observation suggests a possible overlap in the genetic susceptibility 
between the two diseases. This has been supported by previous studies which have 
reported a degree of genetic background that is shared between RA and PsA (29). PsA 
is a seronegative chronic inflammatory joint disease with prevalence rates ranging 
between 0.3 and 1% worldwide (30). It is interesting to note that 14% of a UK 
psoriasis cohort has been found to have co-existing PsA in a previous study (31), 
while 34.85% of a Greek PS cohort in a separate study was found to have PsA (22).  
The spectrum of PsA symptoms includes inflammatory changes in attachments of 
articular capsules, tendons, and ligaments to bone surface(32).  
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A number of candidate gene studies have been carried out in PsA, reporting 
associations with risk loci such as RUNX3, IL23A and TNIP1 (33). Furthermore, a 
strong correlation between an increased risk of PsA and RA-predisposing genes has 
also been identified (29). To date, only one GWAS study has been published that has 
focused solely on PsA (34). However, use of the Immunochip has identified novel 
genome-wide significant PsA susceptibility loci, including PTPN22 (rs2476601) (35). 
As genetic RA-risk factors tend to overlap with PsA (29, 36), the current study was 
undertaken to investigate the association of both diseases with suggestive or 
confirmed RA- and/or PsA-risk genes as well as others that play a key role in the 
pathogenesis of multiple autoimmune diseases. This study focused on the genetic 
homogeneous population of the island of Crete (0.65 million), a population sharing a 
common genetic and cultural background, showing low migration rates and 
characterized by good genealogical records and uniform environmental influences.  
   
Methods  
Patient population and study design 
In this case control association study, 392 RA patients and 126 PsA patients followed 
in the Department of Rheumatology, University Hospital of Heraklion, were included. 
Only RA patients who met the 2010 ACR/EULAR RA Classification Criteria (37) 
and PsA patients who fulfilled the CASPAR criteria (38) and also gave their informed 
consent were eligible for the study. A total of 521 unrelated, age and ethnically 
matched healthy volunteers from the Department of Transfusion Medicine of the 
University Hospital of Crete served as controls. The study was performed in the 
laboratory of Molecular Medicine and Human Genetics of the Medical School of 
Crete, after obtaining the approval of the research committee of the University 
Hospital of Heraklion. 
Analysis of gene polymorphisms 
A panel of single nucleotide polymorphisms (SNPs) mapping to seven previously 
analyzed RA and/or PsA susceptibility loci were selected for genotyping in Greek 
cohorts of RA and PsA patients as well as healthy controls. These included PLCL2 
(rs4535211), CCL21 (rs2812378), REL (rs13017599), STAT4 (rs10181656), CD226 
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(rs763361), PTPN22 (rs2476601) and TYK2 (rs34536443). Genomic DNA was 
isolated from peripheral blood leukocytes using a commercial kit supplied by 
INVITROGEN (PureLink® Genomic DNA Mini Kit) according to the 
manufacturer’s instructions. Allelic discrimination of all SNPs was carried out using 
TaqMan SNP genotyping assays on an Applied Biosystems ViiA™ 7 Real-Time PCR 
System (catalogue ID: C____481392_10, C__16113556_10, C___2833757_10, 
C__30530761_10, C___1464836_20 and C__60866522_10, respectively) from 
Applied Biosystems. Genotyping of rs2476601 SNP of PTPN22 was performed by 
RFLP as described elsewhere (39). All allelic discrimination plots were manually 
reviewed individually for quality. 10% of the samples were amplified twice to ensure 
accuracy of the results. 
Construction of three-dimensional (3-D) model  
Bioinformatic analysis was performed using BlastP (for sequence analysis) on the 
Uniprot sequence database, Pymol (DeLano) for 3D structural positioning and 
visualisation and Maestro and Desmond (Schrodinger Inc.) for mutations and stability 
analysis as well as molecular dynamics. The crystal structure of human TYK2 (pdb 
code 4GVJ) (40) was used as the initial model. 
Statistical analysis 
Statistical analysis was performed with the GraphPad Prism statistical program 
(GraphPad Software, San Diego, CA). In case-control comparisons, only unrelated 
individuals were included. The x
2
 test, with one or two degrees of freedom or Fisher’s 
exact test was used to examine differences of genotype and allele frequencies between 
patients and controls, where all SNPs had a call rate > 98%. A two tailed P value less 
than 0.05 was defined as statistically significant. The gene variants under 
investigation were evaluated for deviation from Hardy–Weinberg equilibrium (HWE)  
by comparing observed and expected genotype frequencies by means of chi-squared 
(x
2
) test or Fisher’s exact test in the control groups (by using the program named 
‘‘Calculate’’; Copyright TRG, SR, INMD, 2008). The distribution of genotypes in the 
case and control groups for all 7 SNPs examined was found to be under HWE (p > 
0.01). Power analysis was conducted using the Quanto (version 1.2.4) program (41-
44). 
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Results  
The average age of the Greek RA cohort was 60.96±12.8 years, and 59.9% of subjects 
were female. Within the Greek PsA cohort, the average age was 52.12±15.41 and 
46% of subjects were female. Unrelated healthy controls (N=521) consisted of 264 
women (50.7%) and 257 men (49.3%) of similar ages. The genotyping was performed 
using TaqMan 5’ allelic discrimination technology with predesigned SNP genotyping 
assays provided by Applied Biosystems. The genotyping success for all the SNPs 
analyzed was >98%. 
Allele and genotype frequencies of the analyzed samples for the TYK2 polymorphism 
(rs34536443) are depicted in Tables 1a and 1b. Our results show that the G/C 
genotype was more frequent in PsA and RA cases than in controls (p=0.019, 
OR=0.099, 95% CI 0.005-1.65 and p=0.033; OR=0.33, 95% CI 0.123-0.90, 
respectively), while the C allele was more frequently observed in PsA patients 
compared to controls (p=0.02, OR=0.10, 95% CI 0.006-1.681). Interestingly, the 
frequency of this allele did not appear to have any statistically significant difference 
between RA patients and controls, although previously it was reported to have a 
potential protective role in RA (45). Bioinformatic analysis revealed that the 
substitution of a G to C nucleotide caused by rs34536443 SNP generates a 
Pro1104Ala mutation in the TYK2 protein. In particular the replacement of the Pro
1104
 
amino acid residue of TYK2 (an α-helical structure disruptor) with an Alanine (an α-
helical former) (Figure 1) may induce to the α-helical segment (residues 1104-1113) a 
conformational change extending the a-helical segment five more residues (1099-
1113). Such a conformational change will probably alter the local 3D structure, affect 
the folding and the interaction parameters of the molecule and therefore induce 
changes in the functionality of the molecule. Molecular dynamics studies of the 
mutant indicate propagation of the folding changes along the molecular structure. 
 
Patients with PsA presented more frequently with the GG genotype and the G allele of 
the STAT4 rs10181656 SNP (P = 0.04, OR=4.3, 95% CI 1.01-18.39 and P = 0.03, 
OR=1.46, 95% CI 1.03-2.08, respectively) (Table 2). These findings support the 
implication of this SNP in the development of PsA in the Greek population. However, 
no association was found between RA cases and controls either at the genotypic or the 
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allelic level (data not shown), contrary to previous results (29). In a first attempt to 
study the functional consequence of the rs10181656 SNP of STAT4, we performed a 
DNA sequence analysis using the Genomatix Software (Genomatix Software GmbH, 
“Gene2Promoter” program, Muenchen, Germany). This analysis revealed that the 
major C allele, but not the minor G allele of the rs10181656 SNP of STAT4, is located 
within a putative binding site for transcription factors Pax-4, PPAR/RXR and ZNF99.  
Association with PsA only was also found for TC genotype of the rs763361 SNP of 
CD226 (p=0.04, OR=0.61, 95% CI 0.39-0.95) (Table 3).  In an attempt to clarify the 
role of this SNP in the development of multiple autoimmune diseases, we analyzed in 
detail the existing 3-D models of this protein (46). The rs763361 SNP results in a 
Gly307Ser substitution; this position is located on the amino acid sequence towards 
the C-terminal end of the CD226 polypeptide. In particular, the Ser
307
 variant alters 
splicing of the CD226 transcript, which affects downstream signaling and increases 
the activation of T and NK cells (47). This region is characterized as the cytoplasmic 
terminal region after the membrane integrated anchoring α-helical part (46). It is 
populated by many charged and polar residues and contains several putative 
phosphorylation sites (Y
249
, T
250
, S
290
, T
293
, S
302
, S
305
, S
313
, Y
322
, Y
325
, S
329
) conserved 
between species. Although no definite conclusions could be drawn about a putative 
structural change, the Ser
307
 residue in the protein’s cytoplasmic region is most likely 
to be involved in polar interactions associated with proximal charged residues or 
phosphorylation sites. 
The distribution of the PTPN22 1858C/T alleles in the Cretan population was not 
significantly different between RA patients and controls (data not shown), while it 
was found that the minor allele T was more common in controls individuals than in 
PsA patients. However, the observed difference was not statistically significant when 
it was evaluated with an x
2
 test of independence (P=0.056, OR=0.27, 95% CI 0.06-
1.14, detailed data not shown).  
Interestingly, none of the remaining three SNPs examined (rs4535211 (PLCL2), 
rs2812378 (CCL21) and rs13017599 (REL) were found to be associated with either 
RA or PsA (data not shown).  
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Our study had 80% power to detect effect sizes of 1.3-1.4 for RA and 1.5 to 1.8 for 
PsA assuming minor allele frequencies of between 10 and 40% at the 5% significance 
level.  
Discussion  
The strategy of studying the putative role of RA susceptibility genetic factors in the 
development of PsA has proven to be highly successful so far (29). Moreover, 
accumulated evidence indicates that ethnic heterogeneity of genetic factors exists for 
rheumatic disorders. Thus, understanding allelic homogeneity and heterogeneity 
among these diseases provides insight into common gene function and pathways. So 
far, the TYK2 rs34536443 (24), the CCL21 rs2812378 (24), the PTPN22 rs2476601 
(24) and the PLCL2 rs4535211 (48) SNPs have been associated with RA, while the 
rs13017599 SNP of REL has been associated with both PsA (49) and RA (50), 
attaining a genome-wide level of significance (P<5e-8) in all cases. Moreover, the 
aforementioned CCL21, PTPN22, PLCL2, REL and STAT4 (rs10181656) SNPs were 
found to be overlapping between RA and PsA in a previous study (29), whereas 
CD226 rs763361 SNP has been associated with an increased risk for the development 
of RA and other autoimmune diseases (51).  
In the current study, the genetic association of STAT4 (rs10181656) and CD226 
(rs763361) with PsA but not with RA was confirmed in a Greek population, while a 
genetic overlap between PsA and RA was detected with the rs34536443 SNP of 
TYK2. The PsA-associated allele of the STAT4 SNP was protective for RA and not 
risk, as previously reported in other populations (29). Importantly, to the best of our 
knowledge, the CD226 SNP has not previously been associated with PsA (51).  
TYK2 is a locus that has been confirmed to be associated with RA at genome-wide 
significance levels (24). The encoded protein is a tyrosine kinase in the STAT 
signaling pathway, important for signaling by type I IFN and induction of Th1 cell 
differentiation upon antigen stimulation of dendritic cells (52). A meta-analysis of 
Immunochip, Exomechip and targeted exon-sequencing data recently demonstrated 
that the minor allele of rs34536443 SNP of TYK2 was protective against RA, 
Systemic Lupus Erythematosus (SLE) and Inflammatory Bowel Disease (IBD) (45), 
while the same variant has been previously reported as conferring risk for  PS) (53) 
and Juvenile Idiopathic Arthritis (JIA) (54). Interestingly, we found the minor allele to 
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increase the susceptibility for RA as well as PsA in the Greek population. However, 
the possibility that the results of our present study are spurious should be considered. 
The location of the Pro1104Ala mutation on the 3D structure of TYK2 may affect 
structural and dynamical elements of the molecule. The introduction of a helical 
former alanine residue to replace the rather constrained helical breaker proline 
influences the secondary structure of this region with an α-helical conformation 
extension, (residues 1099-1113), that may alter folding properties as well as dynamic 
aspects of the molecule which in turn affect its functionality. 
STAT4 encodes a transcription factor that transmits signals induced by several key 
cytokines, including interleukin-12, interleukin-23 and type 1 interferons. STAT4-
dependent signaling by interleukin-12 receptors plays a critical role in the 
development of a Th1-type T-cell response (13). Our bioinformatic analysis showed 
that the minor G allele of the rs10181656 SNP of STAT4 may destroy a putative 
binding site of the heterodimer of transcription factors PPARα/RXRα.  PPARα is a 
nuclear receptor expressed in macrophages, granulocytes and lymphocytes (55, 56) 
and plays an important role in suppressing autoimmune diseases by regulating Th2 
cytokine production (57). Notably, it has been demonstrated that PPARα ligands can 
inhibit T-cell proliferation or the production of IFN-γ by T cells stimulated by 
antigens (58). Thus, it can be hypothesized that the minor allele of rs10181656, which 
was found to have increased frequency in PsA, may suppress T cell activation via the 
disturbance of the binding of the PPARα/RXRα dimer.  
CD226 is a type 1 membrane protein that belongs to the Ig-superfamily and is 
involved in the adhesion and co-stimulation of T cells and NK cells (59-61). The non-
synonymous rs763361 polymorphism of CD226, resulting in a Gly307Ser 
substitution, was suggested to alter the exon-splicing silencer sequence, which may 
affect gene expression. The rs763361 SNP has been found to be associated with RA 
(51), JIA (62), SLE (63), T1D (51), MS (51), Wegener's Granulomatosis (WG) (64), 
MS (65), Autoimmune Thyroid Disease (AITD) (51) and, for the first time, we 
present its association with PsA. Based on a detailed analysis of the existing 3-D 
models of this protein (46), we propose that the Ser
307
 residue is most likely to be 
involved in polar interactions associated with proximal charged residues or 
phosphorylation sites. By affecting the proximal phosphorylation sites or protein-
protein subunit recognition, this mutation could alter the signaling cascade (51). 
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A lower rate of the MAF of PLCL2 (rs4535211), CCL21 (rs2812378) REL 
(rs13017599) and PTPN22 (rs2476601) SNPs has been observed in the healthy 
individuals from Greece compared to those previously described by Bowes et al (29), 
a finding that delineates the role of some existing population-specific differences in 
the frequency of these alleles. A North-South gradient in the frequency of the 
PTPN22 minor allele across Europe has been widely reported previously, ranging 
between 15.5% and 2.1% (36), and will impact on the power to detect association; 
thus, there is still the possibility that increasing the size of the cohort, an association 
of the rs2476601 PTPN22 SNP with RA and/or PsA could be detected. Considering 
the low MAF of the PTPN22 variant in Greek control samples (2.7-3%), more than 
5,000 patient and control samples would be required to detect even a large effect at 
this locus (i.e. a 50% increase in risk with 80% power at p=0.05).  
An advantage of our study was the ethnic matching of the cohort and control group. 
As a consequence, the results are unlikely to be biased by sampling. A clear weakness 
of the study is the limited sample size, especially for PsA. The lack of consistency 
between studies of various RA- and PsA susceptibility loci may be due to the lack of 
power of individual studies to detect the modest effect sizes reported previously at 
most loci.  
Whilst multiple ethnic populations share some of the enormous genetic variation 
detected after the completion of the human genome sequence, a substantial variability 
has been seen in the frequency of many alleles. The different findings of this current 
study from previous ones highlights the importance of comparative studies that 
include different ethnic or racial populations in any attempt to confirm genetic 
associations detected. 
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Figure legends 
 
 
Figure 1: 3D ribbon diagram of the TYK2 native structure (PDB code 4GVJ) 
containing the position of the P1104A polymorphism. Helical regular segments 
are represented in cyan and beta strands in magenta color. Diagram created using 
program PyMol (DeLano et al. Schrodinger Inc). 
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Table 1a. Genotypes and alleles frequency of the TYK2 G/C rs34536443 
polymorphism analyzed in 392 RA patients and 507 healthy controls. 
GENOTYPES 
 
rs34536443 
RA 
N=392 
Controls 
N=507 
p-value OR (95% CI) 
     
G/G 385 (98.2%) 488 (96.3%)   
G/C 5 (1.3%) 19 (3.7%) 0.0347 0.33 (0.123-0.90) 
C/C  2 (0.5%) 0 (0%) 0.1953 6.33 (0.3-132.5) 
ALLELES 
 
G 
 
C 
 
N=784 
      775 (98.9%) 
 
9 (1.1%) 
N=1014 
       995 (98.1%) 
 
19 (1.9%) 
 
 
 
0.25 
 
 
 
0.60 (0.27-1.352) 
 
 
 
Table 1b. Genotypes and alleles frequency of the TYK2 G/C rs3453443 
polymorphism analyzed in 126 PsA patients and 507 healthy controls. 
GENOTYPES 
 
rs34536443 
PsA 
N=126 
Controls 
N=507 
p-value OR (95% CI) 
     
G/G 126 (100%) 488 (96.3%)   
G/C 0 (0%) 19 (3.7%) 0.0194 0.099 (0.005-1.65) 
C/C  0 (0%) 0 (0%)   
ALLELES 
 
G 
 
C 
 
N=252 
      252 (100%) 
 
0 (0%) 
N=1014 
       995 (98.1%) 
 
19 (1.9%) 
 
 
 
0.0203 
 
 
 
0.10 (0.006-1.681) 
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Table 2. Genotypes and alleles frequency of the STAT4 C/G rs10181656 
polymorphism analyzed in 126 PsA patients and 521 healthy controls 
 
GENOTYPES 
 
rs10181656 
PsA 
N=126 
Controls 
N=521 
p-value OR (95% CI) 
     
C/C 82 (65.08%) 295 (56.62%)   
C/G 42 (33.33%) 195 (37.43%) 0.13 3.34 (0.77-14.5) 
G/G  2 (1.59%) 31 (5.95%) 0.04 4.3 (1.01-18.39) 
ALLELES 
 
C 
 
G 
 
N=252 
206 (81.75%) 
 
46 (18.25%) 
N=1042 
785 (75.34%) 
 
257 (24.66%) 
 
 
 
0.03 
 
 
 
 
 
1.46 (1.03-2.08) 
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Table 3. Genotypes and alleles frequency of the CD226 T/C rs763361 polymorphism 
analyzed in 126 PsA patients and 521 healthy controls. 
 
GENOTYPES 
 
rs763361 
PsA 
N=126 
Controls 
N=521 
p-value OR (95% CI) 
     
T/T  48 (38.1%) 148 (28.4%)   
T/C 52 (41.3%) 260 (49.9%) 0.0388 0.61 (0.39-0.95) 
C/C          26 (20.6%)        113 (21.7%) 0.23 0.71 (0.41-1.21) 
ALLELES 
 
T 
 
C 
N=252 
148 (58.7%) 
 
104 (41.3%) 
 
 
N=1042 
556 (53.4%) 
 
486 (46.6%) 
 
 
 
 
 
0.14 
 
 
 
0.80 (0.61-1.06) 
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Figure 1: 3D ribbon diagram of the TYK2 native structure (PDB code 4GVJ) 
containing the position of the P1104A polymorphism. Helical regular segments are 
represented in cyan and beta strands in magenta color. Diagram created using 
program PyMol (DeLano et al. Schrodinger Inc). 
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